Xeris Biopharma Holdings Inc
Research Xeris Biopharma Holdings Inc (XERS) on Bullrun: market cap USD 1.52B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerXERS
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- CurrencyUSD
- Market capUSD 1.52B
- Financial periodQ2 2026
- RevenueUSD 92.10M
- Net income-USD 31.10M
- Free cash flowUSD 8.05M
- Gross margin86.4%
Valuation Snapshot
latest market cap is USD 1.52B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 291.85M | USD 554.00K | USD 27.93M | 85.4% | 0 | USD 111.04M | USD 220.34M | USD 13.69M |
| FY2024 | USD 203.07M | -USD 54.84M | -USD 37.85M | 81.9% | -0.37 | USD 71.62M | USD 232.11M | -USD 29.62M |
| FY2023 | USD 163.91M | -USD 62.26M | n/a | n/a | -0.45 | USD 67.45M | USD 190.93M | -USD 6.78M |
| FY2022 | USD 110.25M | -USD 94.66M | n/a | n/a | -0.7 | USD 121.97M | USD 187.08M | USD 45.19M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 1.52B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.30B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 506.57M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 324.59M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 180.86M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 365.88M | n/a | n/a | n/a |
About Xeris Biopharma Holdings Inc
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Xeris Biopharma Holdings Inc's market cap?
Xeris Biopharma Holdings Inc's market capitalization is USD 1.52B.
What does Xeris Biopharma Holdings Inc do?
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.